l****z
发帖数: 29846 | 1 AstraZeneca slashing 1,200 jobs in Delaware, moving R&D to Gaithersburg
John George
AstraZeneca said Monday it is eliminating 1,200 positions at its Wilmington,
Del., offices, while moving research and development employees to
Gaithersburg.
The Wilmington office will remain the pharmaceutical giant's North American
headquarters.
MedImmune's Gaithersburg headquarters will gain 300 new jobs under the
broader U.S. consolidation by parent company AstraZeneca PLC.
The changes are part of a global restructuring for AstraZeneca, which will
have a new headquarters in Cambridge, England.
AstraZeneca will continue to have about 2,000 position in Wilmington, about
an hour north of Baltimore.
The jobs cuts in Delaware are the result of the exit of the global medicines
development group and the relocation of global marketing, research and
development and U.S. specialty care commercial roles, all of which will now
be based in Gaithersburg.
The changes announced Monday by AstraZeneca (NYSE: AZN) will lead to an
estimated overall reduction of about 650 positions in the U.S., according to
the company.
“The changes we are proposing represent an exciting and important
opportunity to put science at the heart of everything we do because our long
-term success depends on improving R&D productivity and achieving scientific
leadership,” said AstraZeneca CEO Pascal Soriot. “This is a major
investment in the future of this company that will enable us to accelerate
innovation by improving collaboration, reducing complexity and speeding up
decision-making. The strategic centres will also allow us to tap into
important bioscience hotspots providing more of our people with easy access
to leading-edge academic and industry networks, scientific talent and
valuable partnering opportunities.” |
|
